Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2005

View Archived Issues

Amyloidosis and renal disease progression

Q3 progress at Incyte

CombiMatrix and Novavax collaborate on technology for vaccine production

Financing at AM-Pharma to advance programs into phase II

Boehringer Ingelheim and Biolipox partner on drugs for pain and inflammation

Tolvaptan for autosomal dominant polycystic kidney disease

Endogenous stem cell activation for the treatment of Parkinson's

Treating glucose-deprived neurons ameliorates cognitive deficits and oxidative damage

Levosimendan reported effective in the treatment of ADHF

Synairgen begins phase I trial of IFN-beta to reduce asthma exacerbations

tgAAC-09 begins phase II study in South Africa

New approaches to pandemic influenza vaccine development

Phase I/II trial evaluates MGCD-0103 and azacitidine for MDS and AML

Welichem begins new initiatives with Chinese partners

Spectrum reports product development highlights of third quarter

New selective inhibitor of enterovirus replication for myocarditis

Antitumor effects of antibody-drug conjugate targeting glycoprotein NMB

NLNQ-1: a novel hypoxia-selective cytotoxin and radiosensitizer

EP4 agonism as a treatment for diabetic nephropathy

Ghrelin reverses endothelial function in patients with metabolic syndrome

New p38 MAPK inhibitor shows joint-protective effects in rat adjuvant-induced arthritis

Altana withdraws Daxas MAA

Novel FXR activator shows promise in the treatment of hepatic fibrosis

Recent patents describe novel anti-hepatitis agents

New CETP inhibitors disclosed in recent Merck & Co. patent

New treatments for neuropsychiatric disorders claimed in recent patent literature

Update on SCH-503034 in the treatment of hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...